Sawyer & Company Inc Purchases New Shares in Abbott Laboratories $ABT

Sawyer & Company Inc purchased a new position in Abbott Laboratories (NYSE:ABT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,321 shares of the healthcare product maker’s stock, valued at approximately $1,317,000.

A number of other institutional investors also recently modified their holdings of the company. Quadrant Capital Group LLC raised its stake in Abbott Laboratories by 15.6% during the third quarter. Quadrant Capital Group LLC now owns 42,392 shares of the healthcare product maker’s stock worth $4,350,000 after buying an additional 5,705 shares during the last quarter. Newman Dignan & Sheerar Inc. boosted its position in Abbott Laboratories by 48.3% during the third quarter. Newman Dignan & Sheerar Inc. now owns 7,370 shares of the healthcare product maker’s stock valued at $728,000 after acquiring an additional 2,400 shares during the last quarter. Cushing Capital Partners LLC boosted its position in Abbott Laboratories by 8.5% during the third quarter. Cushing Capital Partners LLC now owns 2,926 shares of the healthcare product maker’s stock valued at $289,000 after acquiring an additional 228 shares during the last quarter. Sulzberger Capital Advisors Inc. grew its holdings in Abbott Laboratories by 31.8% during the 3rd quarter. Sulzberger Capital Advisors Inc. now owns 3,511 shares of the healthcare product maker’s stock worth $347,000 after acquiring an additional 848 shares during the period. Finally, Integrated Advisors Network LLC grew its holdings in Abbott Laboratories by 2.2% during the 3rd quarter. Integrated Advisors Network LLC now owns 11,467 shares of the healthcare product maker’s stock worth $1,133,000 after acquiring an additional 252 shares during the period. 75.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Robert W. Baird assumed coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price on the stock. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their target price for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a report on Thursday, August 13th. Finally, Wells Fargo & Company boosted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.88.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter sales of $13.01 billion, up 14.5% year over year and slightly above consensus estimates. Comparable sales increased 7%, while adjusted diluted EPS rose to $1.42 from $1.30 a year earlier. Abbott Reports Third-Quarter 2026 Results
• Positive Sentiment: The company reaffirmed its full-year adjusted EPS guidance, and expanding margins plus new product approvals support Abbott’s longer-term profitability outlook. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Abbott received a European CE Mark for its Cologuard Plus colorectal cancer test, expanding its diagnostics offering and potential market reach in Europe. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: Abbott plans to separate its global Nutrition business—including Similac, Ensure, Glucerna, PediaSure and Pedialyte—into an independent, publicly traded company through a tax-free distribution to shareholders by the end of 2027. Management expects the move to let both businesses pursue more focused growth strategies, but execution, transaction costs and the eventual loss of Nutrition revenue remain important considerations. Abbott Announces Nutrition Business Separation
• Negative Sentiment: Adjusted third-quarter EPS of $1.42 narrowly missed the Zacks consensus estimate of $1.43, making the earnings headline less favorable despite revenue growth. Abbott Misses Q3 Earnings Estimates
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in its Medical Devices business. The softer outlook raised concerns about near-term growth momentum and was the primary fundamental pressure on ABT. Abbott Lowers 2026 Sales Growth Forecast

Abbott Laboratories Stock Down 3.8%

ABT stock traded down $3.92 during trading on Wednesday, reaching $98.53. 14,038,442 shares of the stock were exchanged, compared to its average volume of 11,288,529. The firm’s 50 day moving average is $105.68 and its 200 day moving average is $98.30. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm has a market cap of $170.49 billion, a P/E ratio of 31.95, a price-to-earnings-growth ratio of 1.93 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same quarter in the prior year, the company earned $1.30 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. As a group, research analysts forecast that Abbott Laboratories will post 5.53 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.